Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000

Abstract

From 1981 to 2000, a total of 1823 children with acute myeloid leukemia (AML) enrolled on four consecutive Pediatric Oncology Group (POG) clinical trials. POG 8101 demonstrated that the induction rate associated with the 3+7+7 combination of daunorubicin, Ara-C, and 6-thioguanine (DAT) was greater than that associated with an induction regimen used to treat acute lymphoblastic leukemia (82 vs 61%; P=0.02). Designed as a pilot study to determine the feasibility of administration of noncross-resistant drug pairs and later modified to assess the effect of dose intensification of Ara-C during the second induction course, POG 8498 confirmed the high initial rate of response to DAT (84.2%) and showed that dose intensification of Ara-C during the second induction course resulted in a trend toward higher event-free survival (EFS) estimates than did standard-dose DAT (2+5) during the second induction course (5 year EFS estimates, 22 vs 27%; P=0.33). Age <2 years and leukocyte count <100 000/mm3 emerged as significantly good prognostic factors. The most significant observation made in the POG 8498 study was the markedly superior outcome of children with Down's syndrome who were treated on the high-dose Ara-C regimen. POG 8821 compared the efficacy of autologous bone marrow transplantation (BMT) with that of intensive consolidation chemotherapy. Intent-to-treat analysis revealed similar 5-year EFS estimates for the group that underwent autologous BMT (36±4.7%) and for the group that received only intensive chemotherapy (35±4.5%) (P=0.25). There was a high rate of treatment-related mortality in the autologous transplantation group. The study demonstrated superior results of allogeneic BMT for patients with histocompatible related donors (5-year EFS estimate 63±5.4%) and of children with Down's syndrome (5-year EFS estimate, 66±8.6%). The POG 9421 AML study evaluated high-dose Ara-C as part of the first induction course and the use of the multidrug resistance modulator cyclosporine. Preliminary results showed that patients receiving both high-dose Ara-C for remission induction and the MDR modulator for consolidation had a superior outcome (5-year EFS estimate, 42±8.2%) than did patients receiving other treatment; however, the difference was not statistically significant. These four studies demonstrate the importance of dose intensification of Ara-C in the treatment of childhood AML; cytogenetics as the single most prognostic factor and the unique curability of AML in children with Down's syndrome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 7
Figure 6

Similar content being viewed by others

References

  1. Steuber CP, Civin C, Krischer J, Culbert S, Ragab A, Ruymann FB et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 247–258.

    Article  CAS  Google Scholar 

  2. Steuber CP, Culbert SJ, Ravindranath Y, Krischer J, Ragab A, Civin C et al. Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977–1988). Hamatol Bluttransfus 1990; 33: 198–209.

    CAS  Google Scholar 

  3. Weinstein H, Ravindranath Y, Krischer J, Steuber P, Civin C, Gresik M et al. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML). Leukemia 1992; 6 (Suppl 2): 52–54.

    PubMed  Google Scholar 

  4. Ravindranath Y, Steuber CP, Krischer J, Civin CI, Ducore J, Vega R et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 572–580.

    Article  CAS  Google Scholar 

  5. Kuerbitz SJ, Civin CI, Krischer JP, Ravindranath Y, Steuber CP, Weinstein HJ et al. Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1992; 10: 1419–1429.

    Article  CAS  Google Scholar 

  6. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210–2214.

    CAS  PubMed  Google Scholar 

  7. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J et al. Autologous bone marrow transplantation vs intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428–1434.

    Article  CAS  Google Scholar 

  8. Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M et al. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol 2000; 18: 1867–1875.

    Article  CAS  Google Scholar 

  9. Chang M, Raimondi SC, Ravindranath Y, Carroll AJ, Camitta B, Gresik MV et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down Syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia 2000; 14: 1201–1207.

    Article  CAS  Google Scholar 

  10. Ravindranath YCM, Raimondi S, Carroll AJ, Steuber CP, Camitta B, Weinstein H ed. Prognostic Factors and Patterns of Failure in Childhood Acute Myeloid Leukemia: Experience on Pediatric Oncology Group Study ♯8821. Heidelberg: Springer-Verlag, 2001.

    Google Scholar 

  11. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999; 94: 3707–3716.

    CAS  PubMed  Google Scholar 

  12. Stevens RF, Hann IM, Wheatley K, Gray RG . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130–140.

    Article  CAS  Google Scholar 

  13. Creutzig U, Bender-Gotze C, Ritter J, Zimmermann M, Stollmann-Gibbels B, Korholz D et al. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia 1998; 12: 652–659.

    Article  CAS  Google Scholar 

  14. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56–62.

    Article  CAS  Google Scholar 

  15. Gieseler F, Nussler V, Brieden T, Kunze J, Valsamas S . Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death. Int J Clin Pharmacol Ther 1998; 36: 25–28.

    CAS  PubMed  Google Scholar 

  16. Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier A et al. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996; 93: 903–910.

    Article  CAS  Google Scholar 

  17. Abbott BL, Rubnitz JE, Tong X, Srivastava DK, Pui CH, Ribeiro RC et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia 2003; 17: 2090–2096.

    Article  CAS  Google Scholar 

  18. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U . Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004; 18: 72–77.

    Article  CAS  Google Scholar 

  19. Ravindranath Y . Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 2003; 21: 3385–3387.

    Article  Google Scholar 

  20. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y . Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996; 87: 3395–3403.

    CAS  PubMed  Google Scholar 

  21. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL et al. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 1997; 11: 1594–1595.

    Article  CAS  Google Scholar 

  22. Frost BM, Gustafsson G, Larsson R, Nygren P, Lonnerholm G . Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia 2000; 14: 943–944.

    Article  CAS  Google Scholar 

  23. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002; 100: 3352–3360.

    Article  CAS  Google Scholar 

  24. Ravindranath Y . Down Syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 2003; 21: 3385–3387.

    Article  Google Scholar 

  25. Ravindranath Y . Down Syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 2005; 44: 1–7.

    Article  Google Scholar 

  26. Taub JW, Ge Y . Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005; 44: 33–39.

    Article  Google Scholar 

  27. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.

    Article  CAS  Google Scholar 

  28. Ortega JJ, Diaz de Heredia C, Olive T, Bastida P, Llort A, Armadans L et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica 2003; 88: 290–299.

    PubMed  Google Scholar 

  29. O'Brien TA, Russell SJ, Vowels MR, Oswald CM, Tiedemann K, Shaw PJ et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood 2002; 100: 2708–2716.

    Article  CAS  Google Scholar 

  30. Locatelli F, Labopin M, Ortega J, Meloni G, Dini G, Messina C et al. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 2003; 101: 1611–1619.

    Article  CAS  Google Scholar 

  31. Abella E, Ravindranath Y . Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation. Curr Oncol Rep 2000; 2: 529–538.

    Article  CAS  Google Scholar 

  32. Appelbaum FR . Who should be transplanted for AML? Leukemia 2001; 15: 680–682.

    Article  CAS  Google Scholar 

  33. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001; 19: 2705–2713.

    Article  CAS  Google Scholar 

  34. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 2003; 122: 217–225.

    Article  Google Scholar 

  35. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996; 87: 4979–4989.

    CAS  PubMed  Google Scholar 

  36. Lie SO, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Gustafsson G . A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996; 94: 82–88.

    Article  CAS  Google Scholar 

  37. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19: 1279–1287.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Grant nos. CA-03161, CA-05587, CA-07431, CA-11233, CA-15525, CA-15525, CA-15898, CA-69177, CA-20549, CA-25408, CA-28383, CA-28439, CA-28476, CA-29691, CA-28476, CA-29139, CA-29293, CA-30969, CA-32053, CA-33587, CA-33603, CA-33625, CA-41573, CA-69177, CA-69428, and CA-69428 from the National Institutes of Health, Bethesda, MD.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Y Ravindranath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ravindranath, Y., Chang, M., Steuber, C. et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19, 2101–2116 (2005). https://doi.org/10.1038/sj.leu.2403927

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403927

Keywords

This article is cited by

Search

Quick links